42 studies found for:    " September 14, 2011":" October 14, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Show Display Options
RSS Create an RSS feed from your search for:
" September 14, 2011":" October 14, 2011"[FIRST-RECEIVED-DATE]AND HIV[CONDITION]
Need help? See RSS Feeds
Choose a feed type:
Show studies that were first received in the last 14 daysShow studies that were first received in the last 14 days
Show studies added or modified in the last 14 daysShow studies that were added or modified in the last 14 days
Rank Status Study
1 Unknown  Efficiency of the Hepatitis B Sci-B-Vac Vaccine in HIV Positive Patients
Condition: HIV
Intervention: Biological: Sci-B-Vac
2 Terminated
Has Results
A Study of the Neurological Effects of Adding Raltegravir to HAART Regimen in Patients With HIV
Conditions: Human Immunodeficiency Virus (HIV);   HIV Associated Neurocognitive Disorders (HAND)
Intervention: Drug: Raltegravir
3 Unknown  A Study of the Neurological Effects of Adding Maraviroc to HAART Regimen in Patients With HIV (HANDmac)
Conditions: Human Immunodeficiency Virus (HIV);   HIV Associated Neurocognitive Disorders (HAND)
Intervention: Drug: Maraviroc
4 Active, not recruiting A Commitment Device for Medication Adherence Among HIV Patients
Conditions: Acquired Immunodeficiency Syndrome;   HIV
Intervention: Other: Medication Adherence among HIV/AIDS Patients
5 Active, not recruiting
Has Results
Safety and Efficacy of Cobicistat-boosted Darunavir in HIV Infected Adults
Conditions: Acquired Immunodeficiency Syndrome;   HIV Infections
Interventions: Drug: COBI;   Drug: DRV;   Drug: NRTIs
6 Completed The Prevalence of Neurocognitive Disorder in a Primary Care-based HIV Cohort Compared to a HIV-negative Control Cohort -
Condition: HIV-1-Associated Cognitive Motor Complex
Intervention:
7 Completed Human Immunodeficiency Virus (HIV) Postexposure Prophylaxis (PEP) With Darunavir/Ritonavir (DRV/r)
Condition: Human Immunodeficiency Virus (HIV)
Interventions: Drug: Darunavir/Ritonavir (DRV/r);   Drug: Lopinavir in fixed combination with Ritonavir;   Drug: Zidovudine;   Drug: NRTIs;   Drug: Efavirenz
8 Unknown  The Effect of Probiotics in HIV-1 Infection
Condition: HIV-1 Infection
Interventions: Dietary Supplement: Multi-strain probiotic;   Dietary Supplement: Placebo;   Other: Control
9 Unknown  Dimiracetam in Painful Neuropathies Affecting AIDS Patients
Condition: Acquired Immunodeficiency Syndrome
Interventions: Drug: Dimiracetam;   Drug: Dimiracetam 25 mg
10 Active, not recruiting
Has Results
Dolutegravir Compared to Darunavir/Ritonavir , Each in Combination With Dual Nucleoside Reverse Transcriptase Inhibitors (NRTIs) in ART-naive Subjects
Condition: Infection, Human Immunodeficiency Virus
Interventions: Drug: dolutegravir 50 mg OAD;   Drug: darunavir 800mg OAD;   Drug: ritonavir 100mg OAD
11 Unknown  Comparison of Plasma & SMARTplasma for Human Immunodeficiency Virus (HIV) and Hepatitis C Virus (HCV) Antibody Testing
Conditions: Human Immunodeficiency Virus Infection;   Hepatitis C
Intervention:
12 Active, not recruiting Maternal-fetal CD4 Microchimerism in HiV Exposed Newborns After Spontaneous Delivery and Cesarean Section
Condition: Human Immunodeficiency Virus
Intervention:
13 Unknown  Video-Based Delivery of HIV Test Information for Spanish-Speaking Latinos
Conditions: HIV;   AIDS
Intervention: Behavioral: Video or In-Person Presentation
14 Unknown  Management of Hepatitis C in HIV Infected Injection Drug Users (IDUs)
Conditions: HIV Infection;   Hepatitis C
Intervention: Behavioral: Contigent voucher incentive (CVI)
15 Completed A Study on Antiretroviral Therapy (ART) Naïve Patients On Different Regimens to Treat Hiv (NORTHIV)
Condition: HIV
Interventions: Drug: Lopinavir ritonavir;   Drug: Atazanavir ritonavir;   Drug: Efavirenz
16 Completed Promoting Male Involvement to Improve Prevention of Mother to Child Transmission (PMTCT) Uptake and Reduce Antenatal Infection
Conditions: HIV;   Pregnancy
Interventions: Behavioral: PartnerPlus Intervention;   Other: Usual Care
17 Completed A Key Link for Transmission Prevention
Condition: HIV
Interventions: Behavioral: Standard HIV prevention messages;   Behavioral: 5 counselor-delivered sessions;   Drug: ARVs with raltegravir and emtricitabine/tenofovir disoproxil fumarate
18 Terminated A Phase I Safety and Immunogenicity Preventive Vaccine Trial Based on the HIV-1 Tat and V2-deleted Env Proteins (ISS P-002)
Condition: HIV Infection
Interventions: Biological: HIV-1 Tat/delta-V2 Env combined vaccine;   Biological: HIV-1 delta-V2 Env vaccine;   Biological: HIV-1 Tat vaccine 7.5 microg;   Biological: HIV-1 Tat vaccine 30 microg
19 Recruiting RAltegravir Switch STudy: Effects on Endothelial Recovery
Conditions: HIV Infection;   Endothelial Dysfunction
Intervention: Drug: raltegravir
20 Completed Reducing Cardiovascular Disease (CVD) Risk in HIV on Antiretroviral Therapy Over 12 Months
Conditions: HIV-1 Infection;   Cardiovascular Disease
Interventions: Other: Control;   Other: Intervention Group

   Previous Page Studies Shown (1-20) Next Page (21-40) Show next page of results    Last Page
Indicates status has not been verified in more than two years